Proteomic and metabolic prediction of response to therapy in gastric cancer

World Journal of Gastroenterology

Volumn 20, Issue 38, 2014, Pages 13648-13657

  Aichler, Michaela ^a   Luber, Birgit ^b   Lordick, Florian ^c   Walch, Axel ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Gastric cancer; Matrix assisted laser desorption ionization; Positron emission tomography; Response prediction; Therapy

Indexed keywords

TUMOR MARKER; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

CANCER THERAPY; HUMAN; MASS SPECTROMETRY; METABOLIC PARAMETERS; PROTEIN ANALYSIS; PROTEOMICS; REVIEW; STOMACH CANCER; TREATMENT OUTCOME; GENETICS; METABOLISM; METABOLOMICS; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PROCEDURES; STOMACH NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; HUMANS; MASS SPECTROMETRY; METABOLOMICS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PATIENT SELECTION; PRECISION MEDICINE; PREDICTIVE VALUE OF TESTS; PROTEOMICS; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84910002215     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i38.13648     Document Type: Review

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
2. Ferlay J , Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917 [PMID: 21351269 DOI: 10.1002/ijc.25516]
3. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer 2014; 17: 213-225 [PMID: 24048758 DOI: 10.1007/s10120-013-0297-z]
4. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, Kollmannsberger C, Siewert JR, Fink U. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003; 6: 159-167 [PMID: 14520529 DOI: 10.1007/s10120-003-0245-4]
5. Schuhmacher C , Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010; 28: 5210-5218 [PMID: 21060024 DOI: 10.1200/JCO.2009.26.6114]
6. Sakuramoto S , Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820 [PMID: 17978289 DOI: 10.1056/NEJMoa072252]
7. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730 [PMID: 11547741 DOI: 10.1056/NEJMoa010187]
8. Van Cutsem E , Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997 [PMID: 17075117 DOI: 10.1200/JCO.2006.06.8429]
9. Jiang Y, Ajani JA. Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010; 26: 640-646 [PMID: 20827183 DOI: 10.1097/MOG.0b013e32833efd9b]
10. Persiani R, D'Ugo D, Rausei S, Sermoneta D, Barone C, Pozzo C, Ricci R, La Torre G, Picciocchi A. Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy. J Surg Oncol 2005; 89: 227-36; discussion 237-8 [PMID: 15726615 DOI: 10.1002/jso.20207]
11. Rohatgi PR, Mansfield PF, Crane CH, Wu TT, Sunder PK, Ross WA, Morris JS, Pisters PW, Feig BW, Gunderson LL, Ajani JA. Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. Cancer 2006; 107: 1475-1482 [PMID: 16944539 DOI: 10.1002/cncr.22180]
12. Ninomiya Y, Yanagisawa A, Kato Y, Kitagawa T, Ishihara S, Nakajima T. Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. J Cancer Res Clin Oncol 1999; 125: 699-706 [PMID: 10592104]
13. Nagashima F , Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, Sakata Y, Saito H, Miyata Y, Hyodo I, Ando M. Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 2005; 35: 714-719 [PMID: 16303791 DOI: 10.1093/jjco/hyi194]
14. Jhawer M, Coit D, Brennan M, Qin LX, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol 2009; 32: 356-362 [PMID: 19381079 DOI: 10.1097/COC.0b013e31818c08e8]
15. Mansour JC , Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol 2007; 14: 3412-3418 [PMID: 17909917 DOI: 10.1245/s10434-007-9574-6]
16. Fornaro L , Lucchesi M, Caparello C, Vasile E, Caponi S, Ginocchi L, Masi G, Falcone A. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol 2011; 8: 369-383 [PMID: 21647199 DOI: 10.1038/nrgastro.2011.81]
17. de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: a step forward. World J Gastroenterol 2013; 19: 6165-6169 [PMID: 24115812 DOI: 10.3748/wjg.v19.i37.6165]
18. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008; 19: 1523-1529 [PMID: 18441328 DOI: 10.1093/annonc/mdn169]
19. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
20. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD. Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 2011; 22: 2610-2615 [PMID: 21415234 DOI: 10.1093/annonc/mdr021]
21. Hecht JR, Qin S. Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-031/LOGIC Trial. J Clin Oncol 2013; 13 suppl: abstr LBA4001
22. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/S1470-2045(13)70102-5]
23. Waddell T , Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787 DOI: 10.1016/S1470-2045(13)70096-2]
24. Luber B, Deplazes J, Keller G, Walch A, Rauser S, Eichmann M, Langer R, Höfler H, Hegewisch-Becker S, Folprecht G, Wöll E, Decker T, Endlicher E, Lorenzen S, Fend F, Peschel C, Lordick F. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 2011; 11: 509 [PMID: 22152101 DOI: 10.1186/1471-2407-11-509]
25. Huang H, Han Y, Gao J, Feng J, Zhu L, Qu L, Shen L, Shou C. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients. Med Oncol 2013; 30: 748 [PMID: 24135868 DOI: 10.1007/s12032-013-0748-8]
26. Sekikawa A , Fukui H, Zhang X, Maruo T, Tsumura T, Okabe Y, Wakasa T, Osaki Y, Chiba T, Tomita T, Oshima T, Watari J, Miwa H. REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer. Br J Cancer 2013; 108: 395-401 [PMID: 23322208 DOI: 10.1038/bjc.2012.572]
27. Okada K, Fujiwara Y, Takahashi T, Nakamura Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol 2013; 20: 1035-1043 [PMID: 23054116 DOI: 10.1245/s10434-012-2680-0]
28. Sugita H, Iida S, Inokuchi M, Kato K, Ishiguro M, Ishikawa T, Takagi Y, Enjoji M, Yamada H, Uetake H, Kojima K, Sugihara K. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol Rep 2011; 25: 513-518 [PMID: 21152877 DOI: 10.3892/or.2010.1085]
29. Mitani Y, Oue N, Matsumura S, Yoshida K, Noguchi T, Ito M, Tanaka S, Kuniyasu H, Kamata N, Yasui W. Reg IV is a serum biomarker for gastric cancer patients and predicts response to 5-fluorouracil-based chemotherapy. Oncogene 2007; 26: 4383-4393 [PMID: 17237819 DOI: 10.1038/sj.onc.1210215]
30. Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, Ma L, Zhang W, Meng L, Li Z, Wu J, Jin G, Zhang J, Shou C. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci 2007; 98: 37-43 [PMID: 17052262 DOI: 10.1111/j.1349-7006.2006.00339.x]
31. Qian HG, Shen J, Ma H, Ma HC, Su YH, Hao CY, Xing BC, Huang XF, Shou CC. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol 2005; 11: 6249-6253 [PMID: 16419150]
32. Lim JY, Cho JY, Paik YH, Chang YS, Kim HG. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers 2007; 22: 281-286 [PMID: 18161659]
33. Poon TC, Sung JJ, Chow SM, Ng EK, Yu AC, Chu ES, Hui AM, Leung WK. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 2006; 130: 1858-1864 [PMID: 16697748 DOI: 10.1053/j.gastro.2006.02.011]
34. Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005; 4: 409-418 [PMID: 15684407 DOI: 10.1074/mcp.M500006-MCP200]
35. Röcken C , Ketterlinus R, Ebert MP. Application of proteome analysis to the assessment of prognosis and response prediction in clinical oncology. Curr Cancer Drug Targets 2008; 8: 141-145 [PMID: 18336197]
36. Bateman NW, Sun M, Bhargava R, Hood BL, Darfler MM, Kovatich AJ, Hooke JA, Krizman DB, Conrads TP. Differential proteomic analysis of late-stage and recurrent breast cancer from formalin-fixed paraffin-embedded tissues. J Proteome Res 2011; 10: 1323-1332 [PMID: 21155598 DOI: 10.1021/pr101073s]
37. Ostasiewicz P, Zielinska DF, Mann M, Wis̈niewski JR. Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J Proteome Res 2010; 9: 3688-3700 [PMID: 20469934 DOI: 10.1021/pr100234w]
38. Hood BL , Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 2005; 4: 1741-1753 [PMID: 16091476 DOI: 10.1074/mcp.M500102-MCP200]
39. Shi SR, Liu C, Balgley BM, Lee C, Taylor CR. Protein extraction from formalin-fixed, paraffin-embedded tissue sections: quality evaluation by mass spectrometry. J Histochem Cytochem 2006; 54: 739-743 [PMID: 16399996 DOI: 10.1369/jhc.5B6851.2006]
40. Jiang X, Jiang X, Feng S, Tian R, Ye M, Zou H. Development of efficient protein extraction methods for shotgun proteome analysis of formalin-fixed tissues. J Proteome Res 2007; 6: 1038-1047 [PMID: 17266348 DOI: 10.1021/pr0605318]
41. Guo T, Wang W, Rudnick PA, Song T, Li J, Zhuang Z, Weil RJ, DeVoe DL, Lee CS, Balgley BM. Proteome analysis of microdissected formalin-fixed and paraffin-embedded tissue specimens. J Histochem Cytochem 2007; 55: 763-772 [PMID: 17409379 DOI: 10.1369/jhc.7A7177.2007]
42. Nirmalan NJ, Hughes C, Peng J, McKenna T, Langridge J, Cairns DA, Harnden P, Selby PJ, Banks RE. Initial development and validation of a novel extraction method for quantitative mining of the formalin-fixed, paraffin-embedded tissue proteome for biomarker investigations. J Proteome Res 2011; 10: 896-906 [PMID: 21117664 DOI: 10.1021/pr100812d]